


CLAIMS

1. A compound of formula (I):



wherein:

- 5 R^1 is C_1 - C_4 -alkyl optionally substituted with 1-5 halogen atoms which are the same or different;
- 10 R^2 is $-C_2$ - C_6 -alkynyl, $-C_2$ - C_6 -alkyl- OR^4 , $-(CH_2)_q$ -(C_3 - C_7 -cycloalkyl), $-(CH_2)_q$ -(6- to 12-membered heterobicycloalkyl) containing one, two or three heteroatoms or heteroatom-containing groups independently selected from the group consisting of O, S, $S(=O)$, $S(=O)_2$, and N, $-(CH_2)_q$ -(4- to 7-membered heterocycloalkyl) containing one or two heteroatoms or heteroatom-containing groups independently selected from the group consisting of O, S, $S(=O)$, $S(=O)_2$, and N, or $-(CH_2)_q$ -(5- to 10-membered heteroaryl) containing one, two or three heteroatoms or heteroatom-containing groups independently selected from the group consisting of O, S, and N,
- 15 $-(CH_2)_q$ -(C_3 - C_7 -cycloalkyl), $-(CH_2)_q$ -(6- to 12-membered heterobicycloalkyl) and $-(CH_2)_q$ -(4- to 7-membered heterocycloalkyl) are optionally substituted with one or more substituents which are the same or different, at any ring carbon atom and selected from the group consisting of C_1 - C_4 alkyl optionally substituted with 1-5 halogen atoms which are the same or different, a halogen atom, $-NR^aR^b$, $COOR^5$ and oxo ($=O$),
- 20 $-(CH_2)_q$ -(C_3 - C_7 -cycloalkyl), $-(CH_2)_q$ -(6- to 12-membered heterobicycloalkyl) and $-(CH_2)_q$ -(4- to 7-membered heterocycloalkyl) are optionally substituted with one or more substituents which are the same or different, at any ring carbon atom and selected from the group consisting of C_1 - C_4 alkyl optionally substituted with 1-5 halogen atoms which are the same or different, a halogen atom, $-NR^aR^b$, $COOR^5$ and oxo ($=O$),
- 25 $-(CH_2)_q$ -(C_3 - C_7 -cycloalkyl), $-(CH_2)_q$ -(6- to 12-membered heterobicycloalkyl) and $-(CH_2)_q$ -(4- to 7-membered heterocycloalkyl) are optionally substituted with one or more substituents which are the same or different, at any ring carbon atom and selected from the group consisting of C_1 - C_4 alkyl optionally substituted with 1-5 halogen atoms which are the same or different, a halogen atom, $-NR^aR^b$, $COOR^5$ and oxo ($=O$),

5 wherein any ring nitrogen atom, if present in said
-(CH₂)_q-(6- to 12-membered heterobicycloalkyl) and -(CH₂)_q-
(4- to 7-membered heterocycloalkyl), is independently substituted
with R^c,

10 wherein said -(CH₂)_q-(6- to 12-membered heterobicycloalkyl) and
said -(CH₂)_q-(4- to 7-membered heterocycloalkyl) are attached to
the rest of the molecule via the carbon atom of the -CH₂ group, and

15 wherein the 5- to 10-membered heteroaryl of said -(CH₂)_q-(5- to 10-
membered heteroaryl) is optionally substituted with one or more
substituents which are the same or different, and selected from the
group consisting of C₁-C₄-alkyl optionally substituted with 1-5 halogen
atoms which are the same or different, a halogen atom, -NR^aR^b and -
COOR⁵;

20 R³ is hydrogen or C₁-C₄-alkyl optionally
substituted with 1-5 halogen atoms which are the same or different;

R⁴ and R⁵ are independently hydrogen or C₁-C₄-alkyl;

R^a and R^b are independently hydrogen or C₁-C₄-alkyl;


25 R^c is hydrogen, C₁-C₄-alkyl optionally substituted with 1-
5 halogen atoms which are the same or different, -C(O)O-
C₁-C₄-alkyl, or -C(O)-C₁-C₄-alkyl;

30 A is a 6-membered heteroaryl having one or two nitrogen atom(s)
and is optionally substituted with one or more substituents which
are the same or different, and selected from the group consisting

of a fluorine atom, a chlorine atom, C₁-C₂-alkyl optionally substituted with 1-5 fluorine atoms, and C₁-C₂-alkoxy optionally substituted with 1-5 fluorine atoms; and

5 q is the integer 1.

2. The compound according to claim 1, which is of formula (Ia):



10 3. The compound according to claim 1, wherein
 R¹ is methyl or ethyl.

4. The compound according to claim 1, wherein
 R³ is C₁-C₄-alkyl.

15

5. The compound according to claim 1, wherein
 R³ is methyl.

6. The compound according to claim 1, wherein A is optionally substituted
20 pyrimidinyl, pyridazinyl, pyridinyl, or pyrazinyl.

7. The compound according to claim 6, wherein A is optionally substituted
 pyrimidinyl or pyridazinyl.

25 8. The compound according to claim 7, wherein A is CF₃-pyrimidinyl or 2-CF₃-
 pyrimidin-5-yl.

9. The compound according to claim 1, wherein R^2 is cyclopropylmethyl, tetrahydrofuran-2-ylmethyl, tetrahydrofuran-3-ylmethyl, or tetrahydro-2H-pyran-4-ylmethyl, each of which is optionally substituted.
- 5
10. The compound according to claim 9, wherein R^2 is unsubstituted cyclopropylmethyl.
11. The compound according to claim 1, wherein
- 10 R^2 is $-(CH_2)_q$ -(4- to 6-membered heterocycloalkyl), optionally substituted with one or more substituents which are the same or different, at any ring carbon atom and selected from the group consisting of C_1 - C_4 alkyl optionally substituted with 1-5 halogen atoms which are the same or different, a halogen atom, $-NR^aR^b$, $COOR^5$ and oxo ($=O$),
- 15 wherein any ring nitrogen atom, if present in said $-(CH_2)_q$ -(4- to 6-membered heterocycloalkyl), is independently substituted with R^c ; and
- q is the integer 1.
- 20 12. The compound according to claim 11, wherein R^2 is $-(CH_2)_q$ -morpholinyl substituted with R^c .
13. The compound according to claim 12, wherein R^c is methyl.
- 25 14. The compound according to claim 13, wherein R^2 is (4-methylmorpholin-2-yl)methyl, [(2R)-4-methylmorpholin-2-yl]methyl, or [(2S)-4-methylmorpholin-2-yl]methyl.
15. The compound according to claim 14, wherein R^2 is [(2R)-4-methylmorpholin-2-yl]methyl.
- 30

16. The compound according to claim 11, wherein
 A is pyrimidinyl or pyridazinyl optionally substituted with
 one or two substituents which are the same or different, and selected
 from the group consisting of a fluorine atom, a chlorine atom, C₁-C₂-alkyl
 optionally substituted with 1 to 5 fluorine atoms, and C₁-C₂-alkoxy
 optionally substituted with 1 to 5 fluorine atoms.
17. The compound according to claim 16, wherein
 A is CF₃-pyrimidinyl, 6-CF₃-pyridazinyl, 2-CF₃-pyrimidin-5-yl or 6-CF₃-
 pyridazin-3-yl.
18. The compound according to claim 11, wherein said -(CH₂)_q-(4- to 6-membered
 heterocycloalkyl) is -(CH₂)-morpholinyl for q=1.
19. The compound according to claim 1, which is
 3-(5-ethyl-1,3-thiazol-2-yl)-5-{{(2R)-4-methylmorpholin-2-yl}methoxy}-N-
 {{(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}benzamide;
 3-{{(2R)-4-methylmorpholin-2-yl}methoxy}-5-(5-methyl-1,3-thiazol-2-yl)-N-
 {{(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}benzamide; or
 3-(5-ethyl-1,3-thiazol-2-yl)-5-{{(2R)-4-methylmorpholin-2-yl}methoxy}-N-
 {{(1R)-1-[6-(trifluoromethyl)pyridazin-3-yl]ethyl}benzamide.
20. The compound according to claim 19, which is 3-{{(2R)-4-methylmorpholin-2-
 yl}methoxy}-5-(5-methyl-1,3-thiazol-2-yl)-N-{{(1R)-1-[2-trifluoromethyl)pyrimidin-
 5-yl]ethyl}benzamide.
21. The compound of claim 1, wherein:
 R¹ is C₁-C₄ alkyl;
 R² is optionally substituted -(CH₂)_q-(4- to 6-membered heterocycloalkyl);
 R³ is C₁-C₄ alkyl;

A is optionally substituted pyrimidinyl; and
q is the integer 1.

22. A pharmaceutical composition comprising the compound according to claim 1,
5 and a pharmaceutically acceptable diluent or carrier.
23. The compound according to claim 1 for use in therapy.
24. Use of the compound according to claim 1, in the manufacture of a medicament
10 for treating a disease, condition, or disorder in a patient in need thereof, wherein
said disease, condition, or disorder is hyperalgesia, bladder outlet obstruction,
urinary incontinence, reduced bladder capacity, increased frequency of
micturition, urge incontinence, stress incontinence, bladder hyperreactivity,
overactive bladder, increased urinary frequency, nocturia, urinary urgency,
15 idiopathic bladder hypersensitivity, urethritis, prostatitis, prostatodynia, cystitis,
benign prostatic hypertrophy, prostatic hyperplasia, or detrusor hyperreflexia.
25. Use of the compound according to claim 1 in the manufacture of a medicament
for treating endometriosis, dysmenorrhea, dyspareunia, dysuria, or dyschezia.
20
26. Use of the compound according to claim 1 in the manufacture of a medicament
for treating pain in a patient in need thereof.